Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Gains from Sales and Divestitures (2022 - 2023)

Cytek Biosciences (CTKB) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $260297.0 as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Gains from Sales and Divestitures rose 238.09% year-over-year to $260297.0, compared with a TTM value of $260297.0 through Jun 2023, up 238.09%, and an annual FY2022 reading of $215433.0, changed N/A over the prior year.
  • Gains from Sales and Divestitures was $260297.0 for Q2 2023 at Cytek Biosciences, up from $81639.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $260297.0 in Q2 2023 and bottomed at $76990.0 in Q2 2022.